



Clinical Episode Reconciliation Specifications

Model Years 1 and 2

**Center for Medicare & Medicaid Services (CMS)
Center for Medicare & Medicaid Innovation
(Innovation Center)**

July 2019

TABLE OF CONTENTS

| | | |
|-----------|---|-----------|
| 1 | Inputs | 1 |
| 2 | Outputs | 2 |
| 3 | Clinical Episode Reconciliation Overview | 3 |
| 4 | Calculate Performance Period Clinical Episode Payments | 7 |
| 5 | Calculate Final Target Price | 9 |
| 6 | Calculate Total Performance Period Target Amount | 12 |
| 7 | Calculate Composite Quality Score | 14 |
| | 7.1 Quality Measures | 14 |
| | 7.2 CQS Calculation | 16 |
| 8 | Calculate Reconciliation Amounts | 20 |
| 9 | Calculate True-Up Amounts | 24 |
| 10 | Reconcile ACO Overlap | 27 |
| 11 | Calculate Post-Episode Repayment Amounts | 29 |

LIST OF TABLES AND FIGURES

| | |
|--|----|
| Table 1: Clinical Episode Reconciliation Inputs | 1 |
| Table 2: Clinical Episode Reconciliation Outputs..... | 2 |
| Figure 1. Reconciliation Timeline | 5 |
| Table 3: Model Years 1 and 2 Clinical Episode Date Ranges | 7 |
| Table 4: Preliminary Target Price Updates..... | 10 |
| Table 5: Total Performance Period Target Amount Sample Calculation | 13 |
| Table 6: BPCI Advanced Quality Measures | 15 |
| Table 6 (Continued) | 16 |
| Table 7a. Example of Scaling Raw Quality Scores, Distribution of Raw Quality Scores of the Cohort in the Baseline..... | 17 |
| Table 7b: Example of Scaling Raw Quality Scores, Performance Period Scores | 17 |
| Table 8: Example of Calculating PGP Scores in Hospital-Based Quality Measure Categories... | 18 |
| Table 9: Example of Calculating the Total Number of Applicable Clinical Episodes for Each Quality Measure Category | 19 |
| Table 10: Calculating the CQS | 19 |
| Table 11: Calculate Positive/Negative Reconciliation Amount in Real Dollars | 21 |
| Table 12: Calculate Adjusted Positive/ Negative Reconciliation Amount at the Episode Initiator Level | 22 |
| Table 13: Calculate NPRAs/ Repayment Amounts at the Convener Participant Level | 23 |
| Table 14: Calculate NPRA/Repayment Amount with CQS Payment Adjustment at the Convener Participant Level | 25 |
| Table 15: Calculate True-Up Amount at the Convener Participant Level..... | 26 |

[This page is intentionally left blank.]

1 INPUTS

Table 1: Clinical Episode Reconciliation Inputs

| # | Name | Description |
|---|---|---|
| 1 | BPCI Advanced National and Participant Performance Period Clinical Episodes | The national and Participant set of Clinical Episodes and associated spending amounts in the Performance Period. |
| 2 | Final Target Prices | Prices finalized at the time of reconciliation by replacing the preliminary Patient Case Mix Adjustment (PCMA) with the realized value in the Performance Period. |
| 3 | Quality Measures Data | Individual Quality Measure scores used to calculate Composite Quality Score (CQS) for each Episode Initiator. |
| 4 | Master Data Management (MDM) | These data are used as an input to determine ACO alignment for ACO recoupment calculations. |

2 OUTPUTS

Table 2: Clinical Episode Reconciliation Outputs

| # | Name | Description |
|---|--|---|
| 1 | Net Payment Reconciliation Amount (NPRA) | The amount paid to the Participant by CMS after the reconciliation. |
| 2 | Repayment Amount | The amount paid by the Participant to CMS after the reconciliation. |
| 3 | Post-Episode Spending Repayment Amount | The amount paid by the Participant to CMS after Post-Episode Spending Calculations. |

3 CLINICAL EPISODE RECONCILIATION OVERVIEW

The following document describes the specifications used for semi-annual reconciliation calculations and Post-Episode Spending Calculations for the Bundled Payments for Care Improvement Advanced (BPCI Advanced) model. This document is based on the methodology and outputs from the previous steps of the model that are discussed in the Clinical Episode construction¹ and Target Price construction² specifications documents. To refer to specific steps from the Clinical Episode construction and Target Price construction specifications, this document uses **CE-Step** and **TP-Step**, respectively.

As part of the reconciliation process, for each Participant (both Convener Participant and Non-Convener Participant) CMS compares the fee-for-service allowed amounts from the Episode Initiator's Clinical Episodes against final Target Prices and identifies payments above or below the final Target Price by the defined amount. After applying payment adjustments and capping amounts to limit risk exposure, defined amounts are represented by either the *Net Payment Reconciliation Amount (NPR)* (the amount paid to the Participant by CMS) or the *Repayment Amount* (the amount paid by the Participant to CMS). In addition to calculating reconciliation amounts, CMS performs true-up calculations to update initial reconciliation amounts and prior true-ups using claims processed as of a later date, quality adjustments, and ACO recoupments, where applicable. Finally, for each Participant, CMS calculates and monitors Post-Episode spending between days 91 and 120 of the post-anchor period, referred to as the Post-Episode Monitoring Period, to prevent excess spending in the days following the Clinical Episode period.

Figure 1 contains the timeline for the sequential stages of the reconciliation process for Performance Periods 1 and 2.³ For example, for Participants with Clinical Episodes ending between October 1, 2018 and June 30, 2019 (Performance Period 1), CMS will conduct the initial reconciliation in fall 2019, and first and second true-up calculations in spring 2020 and fall 2020, respectively. Additionally, Model Year 2 Clinical Episodes that end in CY2020 will be reconciled and “trued-up” on the same schedule as the first reconciliation in Model Year 3 (Performance Period 3). Target Price assignment is determined using Anchor end date, and Performance Period is determined using Clinical Episode end date. Quality adjustments based on the Composite Quality Score (CQS) and ACO recoupments will be first applied during the second true-up calculations for Performance Period 1 and the first true-up calculations for Performance Period 2 (Fall 2020). Post-Episode Spending Calculations will initially occur during


¹ “Clinical Episode Construction Specifications Model Years 1 and 2”: <https://innovation.cms.gov/Files/x/bpciadvanced-episodecreationspecs-yr1-2.pdf>

² “BPCI-Advanced-Target-Price-Specifications-Model-Years-1-2”: <https://innovation.cms.gov/Files/x/bpciadvanced-targetprice-my1-2.pdf>

³ See Table 3 for date ranges of each Performance Period in Model Years 1 and 2

the first true-up calculation of each Performance Period and will be recalculated during the second true-up.

Figure 1. Reconciliation Timeline



The next 8 sections contain detailed descriptions of the sequential stages of the reconciliation process.

- **Section 4** provides the methodology for calculating Performance Period Clinical Episode payments in real dollars.
- **Section 5** discusses the methodology for calculating final Target Prices using the updated PCMA and updated Relative Case Mix.
- **Section 6** provides the methodology for calculating Total Performance Period Target Amounts for each Episode Initiator.
- **Section 7** describes quality measures and provides detailed methodology for the calculation and implementation of CQS.

- **Section 8** describes the step-by-step calculation of reconciliation amounts.
- **Section 9** walks through semi-annual true-up calculations.
- **Section 10** describes the methodology for calculating ACO recoupments.
- **Section 11** introduces BPCI Advanced Post-Episode Spending Calculations.

4 CALCULATE PERFORMANCE PERIOD CLINICAL EPISODE PAYMENTS

This section describes steps to calculate Performance Period Clinical Episode payments for each Episode Initiator and Clinical Episode category, using the Performance Period Clinical Episodes with the date ranges detailed in Table 3.

Table 3: Model Years 1 and 2 Clinical Episode Date Ranges

| Performance Periods | Date Range |
|----------------------|--|
| Performance Period 1 | Clinical Episodes with a Clinical Episode end date between 10/1/18 and 6/30/19 ^{4,5} , and start dates on or after 10/1/18 ⁶ . |
| Performance Period 2 | Clinical Episodes with a Clinical Episode end date between 7/1/19 and 12/31/19. ⁷ |
| Performance Period 3 | Clinical Episodes with a Clinical Episode end date on or after 1/1/20, but an Anchor end date on or before 12/31/19. |

⁴ When a Participant terminates participation in the Model, the Participant will be accountable for Clinical Episodes if the Anchor Stay/Anchor Procedure discharge/completion date is prior to the effective date of the termination. Performance Period attribution will be based on Clinical Episode end date.

⁵ Participants will not be assigned Clinical Episodes that begin before the model goes live on 10/1/18.

⁶ Assignment to a Model Year is typically based on Anchor end date. However, in Model Year 1 and 2, there is an additional restriction that the Clinical Episode must start on or after the start of Model Year 1.

⁷ See footnote 4.

- **Step 1. Aggregate Performance Period Clinical Episode payments at the Episode Initiator-Clinical Episode category level:** Use the BPCI Advanced Participant Clinical Episodes ending in the applicable Performance Period to calculate each Episode Initiator’s total spending for a particular Clinical Episode category. Specifically, for each Episode Initiator, sum the standardized allowed amounts across all the Clinical Episodes in that Clinical Episode category. If the Episode Initiator is an acute care hospital (ACH), aggregate spending for all attributed Clinical Episodes initiated at the ACH. If the Episode Initiator is a Physician Group Practice (PGP), aggregate spending for all attributed Clinical Episodes based upon initiating claims billed under the PGP’s TIN, as described in the Clinical Episode Construction Specifications.⁸
- **Step 2. Convert Performance Period Clinical Episode payments to real dollars to obtain final Performance Period Clinical Episode payments:** Convert the Performance Period Clinical Episode payments to real dollars using the following steps:
 - **Step 2a.** Create a ratio of real dollars to standardized dollars by dividing the sum of real Clinical Episode payments by the sum of standardized Clinical Episode payments in the Performance Period for each Episode Initiator and Clinical Episode category.
 - **Step 2b.** Multiply the Performance Period Clinical Episode payments (**Step 1**) by the ratio of real dollars to standardized dollars calculated in **Step 2a**.

⁸ *Performance Period Clinical Episode Payments* $s_{m,ce,t} = \sum_{h \in H} \sum_{i \in T(m,h,ce,t)} Y_{i,m,t}$

where:

i is the specific Clinical Episode

h is the ACH at which the Clinical Episode is initiated

t is the applicable Performance Period

m is the Episode Initiator which can be either an ACH or PGP

ce is the specific Clinical Episode category

Y_{i,m,t} is the standardized Clinical Episode allowed amount

The value *i* ∈ *T(m,h,ce,t)* refers to a Clinical Episode *i* from the set of Clinical Episodes initiated by an Episode Initiator *m* at ACH *h* at time *t*. *T(m,h,ce,t)* will be empty for all ACHs at which the Episode Initiator is not assigned a Clinical Episode.

5 CALCULATE FINAL TARGET PRICE

This section explains how to calculate the final Target Price. The final Target Price methodology updates the preliminary Target Price at the time of reconciliation by using realized Performance Period data to calculate the updated PCMA and the updated Relative Case Mix. This practice ensures that final Target Prices accurately reflect the case mix of the patients treated during a given Performance Period. The Standardized Baseline Spending (SBS) and Peer Adjusted Trend (PAT) Factor remain constant from the preliminary Target Price calculation.⁹ Thus, for ACHs, the updated Hospital Benchmark Price (HBP) is calculated by updating the PCMA term, using the following equation:

$$HBP_{h,u} = SBS_h * PCMA_{u,h} * PAT Factor_h \text{ where}$$

h is the ACH at which the Clinical Episode is initiated, and

u denotes that the term is the updated version.

For PGP Episode Initiators, the updated PGP-ACH Benchmark Price is calculated by updating the Relative Case Mix term so that it compares the Performance Period case mix of the PGP's Clinical Episodes at the ACH, to the baseline period case-mix of the ACH's episodes. The final PGP-ACH Target Price is calculated using the following equation:

$$PGP \text{ ACH Benchmark Price}_{p,h,u} = HBP_{h,i} * PGP \text{ Offset}_{p,h} * Relative \text{ Case Mix}_{p,h,u} \text{ where:}$$

p is the PGP to which the Clinical Episode is attributed;

h is the ACH at which the Clinical Episode is initiated;

i denotes that the term is the preliminary version; and

u denotes that the term has been updated to reflect realized Performance Period spending

The formulas above use components of preliminary Target Prices that are updated during the Model Years to account for the most recently available Medicare payment rates. Specifically, the preliminary Target Prices for Model Years 1 and 2 will be updated three times to align with updates to CMS fee-for-service payment rates. The preliminary Target Prices distributed in May 2018 were based upon the FY 2018 and CY 2018 Final Rules. The preliminary Target Prices distributed in October 2018 and January 2019 reflect FY 2019 and CY 2019 payment rate updates, respectively. The goal of these updates is to maintain an accurate benchmark against which the model compares aggregate fee-for-service payments (AFP). While the group of baseline period Clinical Episodes remains the same, the revised payment rates are used to inflate the spending amounts of these baseline period Clinical Episodes to current Medicare payment

⁹ Though the Medicare payment rate updates will impact the SBS and PAT factor terms, any resulting changes to the Target Price will be delivered to Participants prospectively and therefore will be a part of the Preliminary Target Price.

rates. Risk adjustment is rerun under specifications identical to the first preliminary Target Prices. This results in updated coefficients and, ultimately, updated preliminary Target Prices. The changes to pricing only reflect changes to the relevant prices finalized in the Final Rules. Since, on average, rates increase, it is anticipated that these updates will on average increase preliminary Target Prices. These new preliminary Target Prices are provided to Participants as soon as feasible following publication of the applicable Final Rules in the Federal Register. Preliminary Target Prices will be updated one additional time during Model Years 1 and 2 for the finalized FY 2020 payment rates, which will be applied to Clinical Episodes with an Anchor Stay discharge or Anchor Procedure completion date in 2019Q4. See Table 4 below for dates and payment rate periods pertaining to the updates.

Table 4: Preliminary Target Price Updates

| Preliminary Target Price Estimated Release Date | Preliminary Target Price Effective Date | Applicable FFS Payment Rate Period ¹⁰ |
|---|---|--|
| May 2018 | N/A | FY 2018 and CY 2018 ¹¹ |
| September 2018 | October 1, 2018 | FY 2019 |
| December 2018 | January 1, 2019 | CY 2019 |
| September 2019 | October 1, 2019 | FY 2020 |

These preliminary Target Prices, adjusted for the new Medicare payment rates, will be converted to final Target Prices using the steps described below.

- **Step 3. Determine updated HBP:** To ensure that Target Prices accurately reflect the case mix of the patients treated during a given Performance Period, update the preliminary HBP (**TP-Step 12**) to take into account the realized case mix of the Performance Period that has now ended for each ACH and Clinical Episode category. This requires recalculating the Clinical Episode level patient case mix adjustment amount that comes from the predicted values of the first stage of the risk adjustment model and adjusting the PCMA term and the HBP to account for the updates. This step does not involve rerunning the risk adjustment models.
 - **Step 3a.** For an ACH, apply the beneficiary-level coefficient values from **TP-Step 1** to the Clinical Episodes in the Performance Period. Specifically, rerun **TP-Step 3** using the Performance Period Clinical Episodes to calculate the Clinical Episode-level patient case mix adjustment amount.

¹⁰ Fiscal year payment rate updates will incorporate changes in the Inpatient Prospective Payment System (IPPS), Inpatient Rehabilitation Facility (IRF) and Skilled Nursing Facility (SNF) Final Rules. Calendar year update will incorporate changes in the Outpatient Prospective Payment System (OPPS), Physician Fee Schedule (PFS) and Home Health Agency (HHA) Final Rules. The calendar year updates will also incorporate Medicare Economic Index (MEI).

¹¹ Initial preliminary Target Prices are based on the 2018 payment rates due to availability at the time of workbook distribution

- **Step 3b.** Rerun **TP-Step 10** to calculate the updated PCMA for the ACH and Clinical Episode category by taking the average Clinical Episode-level patient case mix adjustment amount (**Step 3a**) and dividing by the Dollar Amount (**TP-Step 7**). The Dollar Amount is a normalizing factor that is used interpret the SBS in dollars and the PCMA terms as ratios relative to national baseline case mix. It is calculated by taking the average predicted spending for all Clinical Episodes in the national set of Clinical Episodes for a Clinical Episode category, and it remains unchanged from preliminary Target Price construction.
- **Step 3c.** Rerun **TP-Step 12** by multiplying the three components that make up the updated HBP: the SBS (**TP-Step 9**), the updated PCMA (**Step 3b**) and the PAT factor (**TP-Step 11**) for each ACH and Clinical Episode category.
- **Step 4. Determine updated PGP-ACH Benchmark Price:** Calculate the updated PGP-ACH Benchmark Price for each Clinical Episode category by taking into account the PGP's realized case mix at the ACH during the Performance Period that has now ended.
 - **Step 4a.** Rerun **TP-Step 15** to calculate the updated Relative Case Mix using Performance Period Clinical Episodes. Calculate the updated PCMA at the PGP-ACH level by taking the average Clinical Episode-level patient case mix adjustment amount (**Step 3a**) for each PGP-ACH¹² combination and dividing by the Dollar Amount (**TP-Step 7**). Calculate updated Relative Case Mix as the ratio of the final PCMA for each PGP-ACH pair over the preliminary PCMA for the applicable ACH (**TP-Step 10**).
 - **Step 4b.** Calculate the updated PGP-ACH Benchmark Price as the product of the preliminary HBP (**Step 3c**), the PGP Offset (**TP-Step 14**), and the updated Relative Case Mix (**Step 4a**). Note that for PGPs that did not have more than 40 Clinical Episodes for a specific Clinical Episode category in the baseline period, the PGP Offset is 1.
- **Step 5. Determine final Target Prices:** Calculate the final Target Prices by applying the CMS Discount Factor and converting the price from standardized to real dollars.
 - **Step 5a.** Apply a 3% CMS Discount Factor to updated HBPs and updated PGP-ACH Benchmark Prices to calculate the updated Target Prices in standardized dollars for ACHs and PGPs, respectively.
 - **Step 5b.** Calculate final Target Prices by converting the updated Target Prices (**Step 5a**) into real dollars. Multiply the updated Target Prices by a ratio of real dollars to standardized dollars (**Step 2b**) for each Episode Initiator and Clinical Episode category.

¹² Limited to ACHs at which the PGP initiates Clinical Episodes that are assigned to it. Only those ACHs which have more than 40 Clinical Episodes for that Clinical Episode category in the baseline period are considered.

6 CALCULATE TOTAL PERFORMANCE PERIOD TARGET AMOUNT

This section describes how to calculate the Total Performance Period Target Amount based upon the final Target Prices for each of the Episode Initiator's Clinical Episode categories. For ACHs and PGPs practicing at a single ACH, the Total Performance Period Target Amount for each Clinical Episode category is the category volume in the Performance Period multiplied by the Target Price. For PGPs that trigger Clinical Episodes at more than one ACH, the calculation accounts for the volume distribution of Clinical Episodes across ACHs at which they are initiated. To apply the PGP-ACH Target Prices to the overall Clinical Episode category, the PGP's Target Prices are volume-weighted to account for the number of Performance Period Clinical Episodes occurring at each ACH for each Clinical Episode category.

- **Step 6. Determine Total Performance Period Target Amount:** Multiply final Target Prices by Performance Period Clinical Episode volume for each Episode Initiator and Clinical Episode category.¹³
 - **Step 6a.** Count the number of Clinical Episodes assigned to an Episode Initiator for a specific Clinical Episode category in the Performance Period. For a PGP that practices across multiple ACHs, count the number of Clinical Episodes at each ACH separately.
 - **Step 6b.** For each Episode Initiator and Clinical Episode category, multiply the final Target Prices (**Step 5**) by the number of Clinical Episodes in the Performance Period (**Step 6a**). For ACHs or PGPs that initiate Clinical Episodes at a single ACH for the applicable category, the result is the Total Performance Period Target Amount. For PGP Episode Initiators, calculate the Clinical Episode volume-weighted sum of the Target Prices of all the ACHs where the PGP Episode Initiator is assigned Clinical Episodes. The weights are the number of Performance Period Clinical Episodes in a given Clinical Episode category initiated at each ACH during the Performance Period.

Table 5 provides a sample calculation with fabricated data of Total Performance Period Target Amounts for two ACH (H1000 and H2000) and one PGP (P000) Episode Initiators. The PGP, P000, is assigned Clinical Episodes at only one ACH (H1000) for Clinical Episode category CE1 while it is assigned Clinical Episodes across two ACHs (H1000 and H2000) for Clinical Episode category CE2.

¹³ The mathematical expression for the Total Performance Period Target Amount is:

$$\text{Total Performance Period Target Amount}_{m,ce,t} = \sum_{h \in H} \text{Final Target Price}_{m,h,ce,t} * \text{Number of Clinical Episodes}_{m,h,ce,t}$$

where:

Number of Clinical Episodes_{m,h,ce,t} = the sum of all Clinical Episodes in time period T for the given m, h, ce, and t. T(m,h,ce,t) will be empty for all h ∈ H at which the Episode Initiator is not assigned a Clinical Episode.

Table 5: Total Performance Period Target Amount Sample Calculation

| Episode Initiator | PGP/ACH | ACH CCN Associated with Initiating Claim | Clinical Episode Category | Performance Period Clinical Episode Count | Step 2a | Step 5 | | Step 6 |
|-------------------|---------|--|---------------------------|---|---|-------------------------------------|-----------------------------------|---|
| | | | | | Ratio of Real Dollars to Standardized Dollars | Target Price (Standardized Dollars) | Final Target Price (Real Dollars) | Total Performance Period Target Amount (Real Dollars) |
| H1000 | ACH | | CE1 | 34 | 1.01 | \$24,290 | \$24,533 | \$834,122 |
| H1000 | ACH | | CE2 | 15 | 1.04 | \$18,112 | \$18,836 | \$282,540 |
| H1000 | ACH | | CE3 | 28 | 0.99 | \$53,248 | \$52,716 | \$1,476,048 |
| H1000 | ACH | | CE4 | 45 | 0.89 | \$33,039 | \$29,405 | \$1,323,225 |
| H1000 | ACH | | CE5 | 52 | 1.11 | \$24,722 | \$27,441 | \$1,426,932 |
| H2000 | ACH | | CE1 | 12 | 1.02 | \$20,099 | \$20,501 | \$246,012 |
| H2000 | ACH | | CE2 | 1 | 1.01 | \$37,190 | \$37,562 | \$37,562 |
| H2000 | ACH | | CE3 | 14 | 0.86 | \$17,574 | \$15,114 | \$211,596 |
| H2000 | ACH | | CE4 | 150 | 0.93 | \$21,157 | \$19,676 | \$2,951,400 |
| P000 | PGP | H1000 | CE1 | 15 | 1.01 | \$31,434 | \$31,748 | \$476,220 |
| P000 | PGP | H1000 | CE2 | 7 | 1.05 | \$31,898 | \$33,493 | \$545,231 |
| P000 | PGP | H2000 | CE2 | 10 | 1.05 | \$29,598 | \$31,078 | \$545,231 |

Note: Examples are not associated with the fabricated data used in other BPCI Advanced specifications documents. All dollar values are rounded to the nearest dollar and ratios are rounded to two decimal places. For PGPs that initiate Clinical Episodes in the same category across multiple ACHs, Total Performance Period Target Amounts are rolled up to the PGP level. See PGP P000 CE2 for an example.

7 CALCULATE COMPOSITE QUALITY SCORE

An important feature of BPCI Advanced is the use of quality performance data to adjust reconciliation payments made to Participants. By tying payment to performance on quality measures, CMS aims to incentivize providers to improve quality of care while improving efficiency. For each Clinical Episode category and Episode Initiator, up to seven quality measures are weighted to calculate the Composite Quality Score (CQS), which is then applied to the Negative/Positive Total Reconciliation Amounts during true-up calculations to calculate the Adjusted Negative/Positive Total Reconciliation Amount for each Episode Initiator. Using the quality measurement data that are calculated once per year, CQS will be first incorporated in the fall 2020 true-up and continue to be incorporated in any subsequent true-ups for a given Performance Period. The following subsections introduce the BPCI Advanced quality measures and provide the step-by-step methodology for calculating the CQS. Data shown throughout this section are fabricated to illustrate CQS calculations.¹⁴

7.1 Quality Measures

CMS selected seven quality measures to ensure quality performance can be assessed across the full range of Clinical Episode categories offered under the BPCI Advanced model. Table 6 lists quality measures that have been selected to calculate Episode Initiator level CQS for Model Years 1 and 2. CMS may update the list of quality measures for future Model Years.

¹⁴ Fabricated data used in this section are not associated with other fabricated data used throughout the rest of this document or in other BPCI Advanced specifications documents.

Table 6: BPCI Advanced Quality Measures

| Quality Measure | Quality Measure Category Abbreviation | Guiding NQF / PSI # ¹⁵ | Hospital/Physician Based ¹⁶ | MIPS (Y/N) | Applicable Clinical Episode Categories |
|---|---------------------------------------|-----------------------------------|--|------------|--|
| All-cause Hospital Readmission Measure | All-Cause Readmissions | NQF #1789 | Hospital Based | Y | All Inpatient and Outpatient Clinical Episode categories |
| Advance Care Plan | ACP | NQF #0326 | Episode Initiator Based | Y | All Inpatient and Outpatient Clinical Episode categories |
| Perioperative Care: Selection of Prophylactic Antibiotic: First or Second Generation Cephalosporin | Perioperative Care | NQF #0268 | Episode Initiator Based | Y | Back and Neck Except Spinal Fusion (Inpatient and Outpatient) Cardiac Defibrillator Cervical Spinal Fusion Combined Anterior Posterior Spinal Fusion Coronary Artery Bypass Graft (CABG) Double Joint Replacement of the Lower Extremity (DJRLE) Hip and Femur Procedures Except Major Joint Lower Extremity and Humerus Procedure Except Hip, Foot, Femur Major Bowel Procedure Major Joint Replacement of the Lower Extremity (MJRLE) Major Joint Replacement of the Upper Extremity Cardiac Valve Pacemaker |
| Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty and/or Total Knee Arthroplasty | RSCR Following THA/TKA | NQF #1550 | Hospital Based | N | Double Joint Replacement of the Lower Extremity (DJRLE) Major Joint Replacement of the Lower Extremity (MJRLE) |

¹⁵ Please note that several measures were adapted from NQF-endorsed measures; some of the measure specifications were changed for use in the Bundled Payment for Care Improvement Advanced model. NQF has not reviewed or approved the revised measure specifications. Any deviations from these measure specifications will be noted.

¹⁶ This column refers to the level at which the NQF/ PSI measure is calculated. All measures will be applied to all participating Episode Initiators. Where the endorsed measure is hospital-based, the measure is adjusted to apply to the PGP. The NQF-endorsed Perioperative Care measure is physician-based, but it will be adjusted to apply to the hospital. The Advanced Care Plan measure is under review. Note that these represent deviations from NQF/PSI specifications.

Table 6 (Continued)

| Quality Measure | Quality Measure Category Abbreviation | Guiding NQF / PSI # | Hospital/ Physician Based | MIPS (Y/N) | Applicable Clinical Episode Categories |
|---|---------------------------------------|---------------------|---------------------------|------------|--|
| Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Coronary Artery Bypass Graft Surgery | RSMR Following CABG | NQF #2558 | Hospital Based | N | CABG |
| Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction | EDAC After AMI | NQF #2881 | Hospital Based | N | AMI |
| AHRQ Patient Safety Indicators | Composite PSI | PSI #90 | Hospital Based | N | All Inpatient Clinical Episodes |

7.2 CQS Calculation

For each Episode Initiator, performance on multiple quality measures is combined into a CQS that is applied during true-up calculations to the Negative and Positive Total Reconciliation Amounts. Below is a step-by-step methodology for calculating the CQS.

- Step 7. Convert Raw Quality Measures into Scaled Scores:** For each quality measure category and Episode Initiator, scale the raw score by comparing it to the distribution of raw scores among the cohort in the baseline period for that measure. For the quality measure categories that are hospital-based, the cohort is the national set of ACHs and the baseline period is CY2018. All ACHs will be referred to as Episode Initiators in the text below, regardless of whether or not they are participating in the BPCI Advanced model. For the quality measures that are Episode Initiator-based, the cohort is the set of Episode Initiators (ACHs and PGP) that are participating in BPCI Advanced and the baseline period and includes all Clinical Episodes that have both anchor end dates and Clinical Episode end dates in the second half of CY2019. Assign the Episode Initiator a scaled score equal to the percentile to which the Episode Initiator’s raw score would have belonged in the baseline period. If the raw score could have belonged to either of two percentiles, assign the higher one. If an Episode Initiator has a raw score greater than the maximum of the raw scores for the cohort in the baseline period, assign it a scaled score of 100, if an Episode Initiator has a raw score less than the minimum of the raw scores for the baseline period, assign it a scaled score of 0. If an Episode Initiator has no raw quality score, do not assign them a scaled quality score.¹⁷ Please refer to Tables 7a and 7b for an example of scaled quality score determination.

¹⁷ Episode Initiators that do not meet the minimum observation threshold for the quality measure category will be treated as having a missing raw quality score.

Table 7a. Example of Scaling Raw Quality Scores, Distribution of Raw Quality Scores of the Cohort in the Baseline

| Percentile | Raw scores (Score is Higher for Better Performance) | |
|------------|---|-------------|
| | Lower bound | Upper bound |
| 1 | 28 | 32 |
| ... | ... | ... |
| 71 | 49 | 49 |
| 72 | 50 | 53 |
| 73 | 53 | 58 |
| ... | ... | ... |
| 100 | 87 | 90 |

Table 7b: Example of Scaling Raw Quality Scores, Performance Period Scores

| Episode Initiator | Raw Quality Score | Scaled Quality Score |
|-------------------|-------------------|----------------------|
| 0012 | 52 | 72 |
| 1139 | 53 | 73 |
| 5212 | 56 | 73 |
| 4132 | 49 | 71 |
| 1528 | 23 | 0 |
| 3412 | 95 | 100 |
| 2336 | - | - |

- Step 8. For Hospital-Based Quality Measure Categories, Calculate Scaled Quality Scores for the PGPs.** For each combination of PGP and hospital-based quality measure category, calculate the scaled quality measure score as the average of the non-missing scaled quality measure scores of the ACHs at which the PGP initiates Clinical Episodes, weighted by the number of Clinical Episodes across all Clinical Episode categories that were attributed to the PGP and initiated at the ACH during the Performance Period.

Table 8: Example of Calculating PGP Scores in Hospital-Based Quality Measure Categories

| Quality Measure Category | ACH A | | ACH B | | PGP Scaled Quality Score |
|--------------------------|--|----------------------------|--|----------------------------|--------------------------|
| | Count of Performance Period Clinical Episodes Attributed to the PGP and Initiated at ACH A | ACH Scaled Quality Measure | Count of Performance Period Clinical Episodes Attributed to the PGP and Initiated at ACH B | ACH Scaled Quality Measure | |
| All-cause readmissions | 400 | 68 | 100 | 92 | 72.8 |
| RSCR Following THA/TKA | | 38 | | - | 38.0 |
| RSMR Following CABG | | - | | - | - |
| EDAC After AMI | | 22 | | 78 | 33.2 |
| Composite PSI | | 71 | | 87 | 74.2 |

- **Step 9. Compute the Composite Quality Score.**

- **Step 9a.** For each Episode Initiator-quality measure category combination, calculate the total number of Clinical Episodes that the Episode Initiator was attributed across all Clinical Episode Categories that are applicable to the quality measure category.

The example shown in Table 9 is for an Episode Initiator that was attributed Clinical Episodes in IP-AMI, IP-CABG, IP-PCI, and OP-PCI. Of these Clinical Episode categories, only IP-CABG is applicable to the Perioperative Care quality measure category. Note that many Clinical Episodes are included in the total number of applicable Clinical Episodes for multiple quality measure categories.

Table 9: Example of Calculating the Total Number of Applicable Clinical Episodes for Each Quality Measure Category

| | Quality Measure Category Applicable to Clinical Episode Category? | | | | Number of Clinical Episodes Attributed to the Episode Initiator | | | | |
|-------------------------------------|---|---------|--------|--------|---|---------|--------|--------|----------------------|
| | IP-AMI | IP-CABG | IP-PCI | OP-PCI | IP-AMI | IP-CABG | IP-PCI | OP-PCI | Total Applicable CEs |
| Attributed Clinical Episodes | | | | | 200 | 300 | 200 | 1000 | |
| Applicable Clinical Episodes | | | | | | | | | |
| All-Cause Readmission | Y | Y | Y | Y | 200 | 300 | 200 | 1000 | 1700 |
| ACP | Y | Y | Y | Y | 200 | 300 | 200 | 1000 | 1700 |
| Perioperative Care | N | Y | N | N | 0 | 300 | 0 | 0 | 300 |
| RSCR Following THA/TKA | N | N | N | N | 0 | 0 | 0 | 0 | 0 |
| RSMR following CABG | N | Y | N | N | 0 | 300 | 0 | 0 | 300 |
| EDAC After AMI | Y | N | N | N | 200 | 0 | 0 | 0 | 200 |
| Composite PSI | Y | Y | Y | N | 200 | 300 | 200 | 0 | 700 |

- **Step 9b:** Calculate each Episode Initiator’s Composite Quality Score as the average of their non-missing scaled quality scores, weighted by the number Clinical Episodes attributed to the Episode Initiator that are applicable for each quality measure category.

Table 10 continues the example for the Episode Initiator described for Table 9. In this example, the Episode Initiator had enough THA or TKA procedures to receive a quality score for RSCR Following THA/TKA but the Episode Initiator was not attributed any Clinical Episodes that were applicable to this measure (MJRLE or DJRLE Clinical Episodes). Consequently, the RSCR Following THA/TKA quality measure does not contribute to the CQS. Meanwhile, the Episode Initiator had Clinical Episodes for which RSMR following CABG was relevant but a missing quality score for this measure. Due to the missing quality score, RSMR following CABG will not be included in the CQS for this Episode Initiator.

Table 10: Calculating the CQS

| Quality Measure | Scaled Quality Score | Total Applicable CEs | Normalized Weight |
|------------------------|----------------------|----------------------|-------------------|
| All-Cause Readmission | 56.23 | 1700 | 0.370 |
| ACP | 47.17 | 1700 | 0.370 |
| Perioperative Care | 54.21 | 300 | 0.065 |
| RSCR Following THA/TKA | 76.10 | 0 | 0.000 |
| RSMR following CABG | - | 300 | 0.000 |
| EDAC After AMI | 72.24 | 200 | 0.043 |
| Composite PSI | 21.56 | 700 | 0.152 |
| CQS | 48.17 | | |

8 CALCULATE RECONCILIATION AMOUNTS

This section describes how to calculate unadjusted reconciliation amounts that will be disseminated to Participants during the initial reconciliation. The initial reconciliation amount does not adjust for the Episode Initiator's performance on quality measures.¹⁸ This step includes applying the stop-loss/stop-gain provision and calculating NPRA/Repayment Amount. To illustrate how to calculate reconciliation amounts, this section uses fabricated data, presented in Tables 11 through 13. Table 11 shows how to calculate reconciliation payments at the Episode Initiator-Clinical Episode category level. Tables 12 and 13 show how to aggregate these reconciliation amounts to the Episode Initiator and Convener Participant levels respectively.

To calculate reconciliation amounts for Model Years 1 and 2, take the following steps:

- **Step 10 Calculate Positive Reconciliation Amount and Negative Reconciliation Amount at the Clinical Episode category level:** For each Episode Initiator and Clinical Episode category, calculate reconciliation amount as the difference between the Total Performance Period Target Amount (**Step 6**) and final Performance Period Clinical Episode payments (**Step 2**).¹⁹ If the Total Performance Period Target Amount for an Episode Initiator exceeds final Performance Period Clinical Episode payments during the Performance Period, it results in a Positive Reconciliation Amount. If the Total Performance Period Target Amount is less than the final Performance Period Clinical Episode payments, the result is a Negative Reconciliation Amount.

¹⁸ Note that quality adjustments will be applied to reconciliation amounts in the true-up calculations through the CQS. For all initial reconciliations and initial true-ups occurring in spring, when the CQS is not yet available, the temporary CQS will be a 0 out of 100 for all Episode Initiators, pending replacement.

¹⁹ Represented mathematically as *Positive/Negative Reconciliation Amount*_{m,ce,t} = *Total Performance Period Target Amount*_{m,ce,t} – *Final Performance Period Clinical Episode Payment*_{m,ce,t}

Table 11: Calculate Positive/Negative Reconciliation Amount in Real Dollars

| Episode Initiator | PGP/ACH | Clinical Episode Category | Number of Performance Period Clinical Episodes | Step 2a | Final Performance Period Clinical Episode Payments | | Total Performance Period Target Amount | Step 10 |
|-------------------|---------|---------------------------|--|---|--|--------------|--|---|
| | | | | Ratio of Real Dollars to Standardized Dollars | Step 1 | Step 2b | Step 6 | Positive/Negative Reconciliation Amount in Real Dollars |
| | | | | | Standardized Dollars | Real Dollars | Real Dollars | |
| H1000 | ACH | CE1 | 34 | 1.01 | \$945,744 | \$955,201 | \$834,122 | -\$121,079 |
| H1000 | ACH | CE2 | 15 | 1.04 | \$378,315 | \$393,448 | \$282,540 | -\$110,908 |
| H1000 | ACH | CE3 | 28 | 0.99 | \$1,452,500 | \$1,437,975 | \$1,476,048 | \$38,073 |
| H1000 | ACH | CE4 | 45 | 0.89 | \$2,422,260 | \$2,155,811 | \$1,323,225 | -\$832,586 |
| H1000 | ACH | CE5 | 52 | 1.11 | \$1,540,812 | \$1,710,301 | \$1,426,932 | -\$283,369 |
| H2000 | ACH | CE1 | 12 | 1.02 | \$215,328 | \$219,635 | \$246,012 | \$26,377 |
| H2000 | ACH | CE2 | 1 | 1.01 | \$20,798 | \$21,006 | \$37,562 | \$16,556 |
| H2000 | ACH | CE3 | 14 | 0.86 | \$215,166 | \$185,043 | \$211,596 | \$26,553 |
| H2000 | ACH | CE4 | 150 | 0.93 | \$3,198,300 | \$2,974,419 | \$2,951,400 | -\$23,019 |
| P000 | PGP | CE1 | 15 | 1.01 | \$238,218 | \$240,600 | \$476,220 | \$235,620 |
| P000 | PGP | CE2 | 17 | 1.05 | \$231,963 | \$243,561 | \$545,231 | \$301,670 |

Note: Examples are not associated with the fabricated data used in other BPCI Advanced specifications documents. All dollar values are rounded to the nearest dollar and ratios are rounded to two decimal places.

- Step 11. Calculate Positive Total Reconciliation Amount and Negative Total Reconciliation Amount at the Episode Initiator level:** For an Episode Initiator, aggregate Positive Reconciliation Amounts and Negative Reconciliation Amounts (**Step 10**) across all Clinical Episode categories to obtain either Positive Total Reconciliation Amount or Negative Total Reconciliation Amount.
- Step 12. Calculate Adjusted Positive Total Reconciliation Amount and Adjusted Negative Total Reconciliation Amount at the Episode Initiator Level:** For the initial reconciliation, calculate the Adjusted Positive Total Reconciliation Amount and the Adjusted Negative Total Reconciliation Amount by temporarily withholding the potential CQS adjustment outlay at risk (i.e., 10% for Model Years 1 and 2) to the Positive Total Reconciliation Amount and the Negative Total Reconciliation Amount. Specifically, at the Episode Initiator level, the Adjusted Positive Total Reconciliation Amount will equal 90% of the Positive Total Reconciliation Amount, while the Adjusted Negative Total Reconciliation Amount will equal the Negative Total Reconciliation Amount.²⁰ This is the equivalent of CQS of zero and ensures that Participants will only receive increases (or no change) in their Adjusted Total Reconciliation Amount associated with their CQS

²⁰ If $Total\ Reconciliation\ Amount_{m,t} > 0$ then $Adjusted\ Total\ Reconciliation\ Amount_{m,t} = Total\ Reconciliation\ Amount_{m,t} * 0.9$. If $Total\ Reconciliation\ Amount_{m,t} < 0$ then $Adjusted\ Total\ Reconciliation\ Amount_{m,t} = Total\ Reconciliation\ Amount_{m,t}$. Where Total Reconciliation Amount is represented mathematically as $Total\ Reconciliation\ Amount_{m,t} = \sum_{ce \in CE} * Reconciliation\ Amount_{m,ce,t}$

during true-up calculations.²¹ During the true-up reconciliations occurring in fall each year, as applicable, apply the CQS Adjustment Amount to the Positive Total Reconciliation Amount and Negative Total Reconciliation Amount to revise the Adjusted Positive Total Reconciliation Amount and Adjusted Negative Total Reconciliation Amount respectively from earlier reconciliation calculations when the CQS was not available (see **Step 18** for more details.)

- **Step 13. Apply the 20% stop-loss/stop-gain provision:** As shown in Table 13, if the Episode Initiator’s Adjusted Positive Total Reconciliation Amount (**Step 12**) is greater than 20% of the Total Performance Period Target Amount (**Step 6**) or if the absolute value of its Adjusted Negative Total Reconciliation Amount is greater than 20% of the Total Performance Period Target Amount, then apply the 20% stop-loss/stop-gain provision.²² The Adjusted Positive/Negative Total Reconciliation Amount that incorporates 20% stop-loss/stop-gain where applicable is the capped Adjusted Positive/Negative Total Reconciliation Amount.

Table 12: Calculate Adjusted Positive/ Negative Reconciliation Amount at the Episode Initiator Level

| Episode Initiator | Step 11 | Step 12 | Step 6 | Step 13 | Step 13 |
|-------------------|---|--|---|---------------------------|--|
| | Positive/Negative Total Reconciliation Amount | Adjusted Positive/Negative Total Reconciliation Amount | 20% of Total Performance Period Target Amount | Apply Stop-Loss/Stop-Gain | Capped Adjusted Positive/ Negative Total Reconciliation Amount |
| H1000 | -\$1,309,869 | -\$1,309,869 | \$1,068,573 | Yes | -\$1,068,573 |
| H2000 | \$46,467 | \$41,820 | \$689,314 | No | \$41,820 |
| P000 | \$537,290 | \$483,561 | \$204,290 | Yes | \$204,290 |

Note: Examples are not associated with the fabricated data used in other BPCI Advanced specifications documents. All dollar values are rounded to the nearest dollar.

- **Step 14. Calculate NPRAs and Repayment Amounts:** As shown in Table 13, for each Participant, aggregate the capped Adjusted Positive/ Negative Total Reconciliation Amount (Step 13) across all applicable Episode Initiators to obtain either NPRA or

²¹In subsequent true-up calculations when an updated CQS is available, the application of a CQS adjustment will result in either no change to, in the case of a CQS of zero, or a positive adjustment to, either the Adjusted Positive Total Reconciliation Amount or Adjusted Negative Total Reconciliation Amount, in the case of a CQS which exceeds 0.

²² Represented as:

If Adj Positive Total Reconciliation Amount, then $\min(\text{Adj Positive Total Reconciliation Amount}, 20\% \text{ of Total Performance Period Target Amount})$,

If Adj Negative Total Reconciliation Amount, then $\min(\text{abs}(\text{Adj Negative Total Reconciliation Amount}), 20\% \text{ of Total Performance Period Target Amount})$

Repayment Amount. Skip this step if the Episode Initiator is a Non-Convener Participant.²³

Table 13: Calculate NPRAs/ Repayment Amounts at the Convener Participant Level

| Episode Initiator | Step 13 | Step 14 |
|-------------------|--|---------------------------------------|
| | Capped Adjusted Positive/ Negative Total Reconciliation Amount | Convener-Level NPRA/ Repayment Amount |
| H1000 | -\$1,068,573 | -\$822,463 |
| H2000 | \$41,820 | |
| P000 | \$204,290 | |

Note: This table assumes H1000, H2000, and P000 from Table 13 are now the complete list of Episode Initiators under the Convener Participant. Examples are not associated with the fabricated data used in other BPCI Advanced specifications documents. All dollar values are rounded to the nearest dollar.

²³ For a Non-Convener Participant, the capped Adjusted Positive/Negative Total Reconciliation amount in Step 13 is the NPRA/ Repayment Amount, respectively.

9 CALCULATE TRUE-UP AMOUNTS

This section describes how to perform true-up calculations to update initial reconciliation amounts and prior true-ups using claims processed as of a later date as well as quality measure data. True-ups are conducted six months and one year after initial reconciliation occurs. Both true-up calculations will factor in newly processed claims. Quality measurement data that is calculated once per year, will be first incorporated in the Fall true-up and continue to be incorporated in any subsequent true-ups for a given Performance Period.²⁴ ACO recoupments (described in the following section), however, will only be incorporated for each Performance Period once per year during the fall true-up. To illustrate true-up calculations, this section uses fabricated data.²⁵

- **Step 15. Recalculate Performance Period Clinical Episode Payments:** Using the set of newly processed claims data, follow **Steps 1-2** to calculate final Performance Period Clinical Episode payments.
- **Step 16. Recalculate Final Target Prices and Total Performance Period Target Amounts:** Using the new set of claims data, follow **Steps 3-6** to calculate final Target Prices and Total Performance Period Target Amounts. Note that the updated set of claims data will only reflect changes in Target Price components that use realized Performance Period data, i.e. updated PCMA, updated Relative Case Mix, and realized ratio of real to standardized dollars.
- **Step 17. Recalculate Reconciliation Amounts:** Follow **Steps 10-11** to recalculate Positive and Negative Total Reconciliation Amounts at the Episode Initiator level.
- **Step 18. Incorporate CQS into Positive/Negative Total Reconciliation Amount:** Apply the CQS Adjustment Amount to the Positive Total Reconciliation Amount and Negative Total Reconciliation Amount using the following steps. Table 14 below shows how this calculation is implemented using the example from Section 8.
 - **Step 18a.** Calculate the CQS Adjustment Amount, which reflects the amount by which the Total Reconciliation Amount will be adjusted as a result of the Episode Initiator's performance on the CQS. First, calculate the CQS Adjustment Percent. For Model Years 1 and 2, the maximum percent at risk is 10%; thus an Episode Initiator may have the magnitude of its Total Reconciliation Amount reduced by 0 to 10%. For Positive Total Reconciliation Amounts, the CQS Adjustment Percent is inversely proportional to the CQS and scaled to 10% (i.e., CQSs of 0 and 100 have CQS

²⁴ For Performance Period 1 2019, CQS will be applied for the first time to the second true-up; while for Performance Period 2 2019, CQS will be applied for the first time to the first true-up and carried through to the second.

²⁵ Fabricated data used in this section are not associated with fabricated data used in other BPCI Advanced specifications documents.

Adjustment Percentages of 10% and 0%, respectively). For Negative Total Reconciliation Amounts, the CQS Adjustment Percent is proportional to the CQS and scaled to 10% (i.e., CQSs of 0 and 100 have CQS Adjustment Percentages of 0% and 10%, respectively). Please refer to the equation in the footnote for the exact calculation.²⁶ Next, multiply the CQS Adjustment Percent by the Episode Initiator-level Total Reconciliation Amount to get the CQS Adjustment Amount, which will be positive for Positive Total Reconciliation Amounts, and negative for Negative Total Reconciliation Amounts.

- **Step 18b.** Subtract the CQS Adjustment Amount from the Episode-Initiator level Total Reconciliation Amount (**Step 17**) to get the Adjusted Total Reconciliation Amount for each Episode Initiator. For Negative Total Reconciliation Amounts this corresponds to a reduction in the amount owed to CMS (provided the CQS Score was greater than 0), and for Positive Total Reconciliation Amounts this corresponds to a decrease in the amount CMS owes the Participant (provided the CQS Score was less than 100).
- **Step 18c.** Repeat **Step 13** to apply the 20% stop-loss/stop-gain provision to get the capped Adjusted Positive/Negative Total Reconciliation Amount for each Episode Initiator.
- **Step 18d** For Convener Participants, sum all their Episode Initiators' capped Adjusted Positive Total Reconciliation Amounts and Adjusted Negative Total Reconciliation Amounts to obtain NPRA/Repayment Amount.

Table 14: Calculate NPRA/Repayment Amount with CQS Payment Adjustment at the Convener Participant Level

| Episode Initiator | Step 17 | Step 9 | Step 18a | | Step 18b | Step 18c | Step 18c | Step 18c | Step 18d |
|-------------------|---|--------|------------------------|-----------------------|--|-------------------------------------|---------------------|---|--------------------------------------|
| | Positive/Negative Total Reconciliation Amount | CQS | CQS Adjustment Percent | CQS Adjustment Amount | Adjusted Positive/Negative Total Reconciliation Amount | 20% of Volume Weighted Target Price | Stop-Loss/Stop-Gain | Capped Adjusted Positive/Negative Total Reconciliation Amount | Convener-Level NPRA/Repayment Amount |
| H1000 | -\$1,309,869 | 50 | 5% | -\$65,493 | -\$1,244,376 | \$1,068,573 | Yes | -\$1,068,573 | -\$819,675 |
| H2000 | \$46,467 | 65 | 4% | \$1,859 | \$44,608 | \$689,314 | No | \$44,608 | |
| P000 | \$537,290 | 77 | 2% | \$10,746 | \$526,544 | \$204,290 | Yes | \$204,290 | |

Data shown are from the initial reconciliation calculation examples. In practice, true-up calculations will use newly processed claims data. Examples are not associated with the fabricated data used in other BPCI Advanced specifications documents. All dollar values are rounded to the nearest dollar.

²⁶ Represented mathematically as $CQS\ Adjustment\ Amount_{m,t} = CQS\ Adjustment\ Percent_{m,t} * Total\ Reconciliation\ Amount_{m,t}$ where:

$$CQS\ Adjustment\ Percent_{m,t} = \begin{cases} \text{if } Total\ Reconciliation\ Amount_{m,t} > 0 \text{ then, } \left(10\% - 10\% * \frac{CQS_{m,t}}{100}\right) \\ \text{if } Total\ Reconciliation\ Amount_{m,t} < 0 \text{ then, } 10\% * \frac{CQS_{m,t}}{100} \end{cases}$$

- **Step 19. Calculate True-Up amount:** Once the NPRA/Repayment Amounts are calculated for the true-up cycle, calculate true-up amount for each Participant by comparing the new amount with the previous amount. For a Participant, the true-up amount will be the difference between the NPRA/Repayment Amount in the current true-up period and NPRA/Repayment Amount in the previous period.²⁷

Table 15: Calculate True-Up Amount at the Convener Participant Level

| Step 18d | Step 14 | Step 19 |
|------------------------------------|---|----------------|
| Recalculated NPRA/Repayment Amount | NPRA/Repayment Amount from Previous Calculation | True-Up Amount |
| -\$819,675 | -\$822,463 | \$2,788 |

The True-Up amount is always calculated as the difference between the NPRA/Repayment Amount calculated for the current True-Up period and the most recent previous NPRA/Repayment Amount calculation.

²⁷ Represented mathematically as $True-Up Amount_{P,t} = NPRA Amount/Repayment Amount_{P,t} - NPRA Amount/Repayment Amount_{P,(t-1)}$, where,
P is the Participant
t is the applicable Performance Period
(t-1) is the previous Performance Period

10 RECONCILE ACO OVERLAP

BPCI Advanced Participants aligned with an Accountable Care Organization (ACO), including the Medicare Shared Savings Program 1, 1+, and 2, will have the portion of the BPCI Advanced discount paid out as the ACO's shared savings payment recouped, to account for overlapping savings achieved for the same beneficiary's care. Recoupment calculations occur after the completion of the shared savings calculation under the relevant ACO initiative and will first occur during the second true-up calculations for Performance Period 1 2019 (includes Clinical Episodes ending in 2018, if any) and the first true-up calculations for Performance Period 2 2019 (during the Fall 2020 Reconciliation).

- **Step 20. Identify Participants aligned with an ACO:** An Episode Initiator is considered a participant in an ACO if it:
 - Has or bills through a TIN that appears on a Shared Savings Program ACO's certified list of ACO participants;
 - Has a CCN included on an ACO's participating provider list;
 - Or has a TIN/NPI combination included on an ACO's participating provider list.
- **Step 21. Check if the ACO achieved savings:** Using information from the MDM, check if an ACO achieved savings. If an ACO achieved savings, proceed to **Step 22**, otherwise skip the remaining steps in this section.
- **Step 22. Calculate BPCI Advanced Discount Amount:** The BPCI Advanced Discount Amount equals the dollar amount of the CMS Discount Factor (i.e., 3%). For instance, if a Participant's Benchmark Price is \$30,000, the BPCI Advanced Discount Amount is \$900 (3% of the Benchmark Price.)
- **Step 23. Determine the Shared Savings Percentage:** Using MDM data, determine the savings rate achieved by the ACO after completion of its Performance Period.
- **Step 24. Calculate the Scaling factor:** Use the components below to calculate the scaling factor:
 - **Step 24a.** Calculate ACO spending as the aggregate Parts A and B expenditures for beneficiaries aligned with that ACO. Using the BPCI Advanced Discount (**Step 22**), calculate the BPCI Advanced Discount Amount as a percent of ACO spending.
 - **Step 24b.** Calculate national spending as the aggregate Parts A and B expenditures for the national population. Using the BPCI Advanced Discount Amount (**Step 22**), calculate the BPCI Advanced Discount Amount as a percent of national spending.

- **Step 24c.** The Scaling factor is equal to one minus the BPCI Discount as a percent of national spending (**Step 24b**) divided by the BPCI Discount as a percent of ACO spending (**Step 24a**).²⁸
- **Step 25. Calculate the BPCI Advanced recoupment amount:** The BPCI Advanced recoupment amount is equal to the product of the BPCI Advanced Discount Amount (**Step 22**), the Shared Savings Percentage (**Step 23**), and the Scaling Factor (**Step 24**).²⁹

²⁸ Represented mathematically as:
$$\text{Scaling Factor} = 1 - \frac{\text{BPCI Discount as percent of national spending}}{\text{BPCI Discount as percent of ACO spending}}$$

²⁹ Represented mathematically as $\text{BPCI Advanced Recoupment Amount} = \text{BPCI Advanced Discount Amount} * \text{Shared Savings Percentage} * \text{Scaling Factor}$

11 CALCULATE POST-EPIISODE REPAYMENT AMOUNTS

To reduce Participants' incentives to withhold or delay medically-necessary care until after a BPCI Advanced Clinical Episode ends, BPCI Advanced Participants are responsible for statistically implausible increases in post-episode spending between days 91 and 120 of the post-anchor period. This time period will henceforth be referred to as the Post-Episode Monitoring Period. The Post-Episode Spending Calculations for a Performance Period will occur at the same time as the first true-up calculations and will be recalculated during the second true-up to account for newly processed claims. For example, Participants with Clinical Episodes ending between October 2018 and June 2019 will receive their first Post-Episode Spending Calculations in spring 2020.

- **Step 26. Attribute services and payments to the Post-Episode Monitoring Period:** Considering all baseline period and Performance Period Clinical Episodes, attribute Parts A and B claims with a standardized payment amount greater than zero that overlap with days 91-120 of the post-anchor period.
- **Step 27. Apply payment aggregation logic for the Post-Episode Monitoring Period:** For baseline period and Performance Period Clinical Episodes, follow **CE-Steps 14-18** to:
 - Apply BPCI Advanced exclusions criteria,
 - Prorate claims that extend before or after the Post-Episode Monitoring Period, and
 - Calculate overall Post-Episode Spending payment amounts.³⁰
- **Step 28. Apply Setting-Specific Price Update Factor Associated with the Preceding Clinical Episode:** For constructing baseline period Post-Episode Spending, follow **CE-Steps 19-21** to update payments occurring in the Post-Episode Monitoring Period to Performance Period dollars. Assign post-episode spending to baseline years using the Anchor end date of the preceding Clinical Episode.
- **Step 29. Calculate Post-Episode Spending Benchmark:** Run the two-stage risk adjustment model to estimate baseline Clinical Episode spending for the Post-Episode Monitoring period following **TP-Steps 1-16**. Obtain ACH and PGP-ACH benchmarks for Post-Episode monitoring period.
- **Step 30. Calculate Performance Period Post-Episode spending:** For all attributed Performance Period Clinical Episodes, aggregate Performance Period post-episode spending amounts to the Clinical Episode category level following the methodology in **Step 2**.

³⁰ Note that because the Post-Episode Spending Calculations are aimed at deterring providers from shifting costs to the Post-Episode Monitoring Period; Post-Episode Spending payments are not winsorized.

- **Step 31. Convert Post-Episode Spending Benchmark and Performance Period Post-Episode spending to real dollars:** Convert the post-episode spending benchmark and Performance Period post-episode spending to real dollars by multiplying each amount by a ratio of the sum of real post-episode spending to sum of standardized post-episode spending in the Performance Period for each Episode Initiator and Clinical Episode category.
- **Step 32. Calculate Total Performance Period Post-Episode Benchmark Amount:** For each Episode Initiator and Clinical Episode category, multiply the final post-episode spending benchmark by the number of Clinical Episodes in the Performance Period (See Step 6a).
- **Step 33. Reconcile upper bound of Total Performance Period Post-Episode Benchmark Amount against realized Performance Period Post-Episode Spending:** If Performance Period Post-Episode spending minus the upper bound of the 99.5% confidence interval of the predicted Total Post-Episode Benchmark Amount is greater than zero, this amount represents Post-Episode Spending Repayment Amount owed to Medicare.
- **Step 34. Calculate Post-Episode Spending Repayment Amounts at the Convener level:** For all Episode-Initiators under a Convener, sum the Post-Episode Spending Repayment Amounts to the Convener level.
- **Step 35. Recalculate Post-Episode Spending Repayment Amount:** During the second true-up calculation for each Performance Period, repeat Steps 26-34 using newly processed claims.
- **Step 36. Calculate Post-Episode Spending Repayment True-Up amount:** Once the new amounts are calculated for the true-up cycle, calculate true-up amount for each Participant by comparing the new amount with the previous amount.